memo inOncology SPECIAL ISSUEcongress report ESMO 2020 with focuson solid tumors is now available!

Although the COVID-19 pandemic has still prevented on-site attendance at this year’s ESMO meeting (September 18th– September 21st), the global oncology community presented a large range of relevant and potentially practice-changing findings. This report highlights the milestones of PD-1 inhibition in gastric and esophageal cancer with practice-changing innovations implemented from the laboratories into clinical practice. Moreover, new treatment strategies for patients with ovarian cancer are presented in the section taking PARP inhibition one step further. Last but not least, this special issue includes novel combination approaches in various other solid tumors.

As an additional feature, you will find expert video interviews with ESMO President Andrés Cervantes and Eric van Cutsem on various conference highlights on our website.

Access an article directly (Mandarin):

·  序言

·  胃癌和食管癌中PD-1抑制取得的里程碑式进展

·  将创新从实验室带入临床实践

·  卵巢癌：将PARP抑制更进一步

·  多种实体瘤中的新型组合方法

Access an article directly (English):

·  Preface

·  Milestones of PD-1 inhibition in gastric and esophageal cancer

·  Getting innovation from the laboratories into clinical practice 

·  Ovarian cancer: taking PARP inhibition one step further 

·  Novel combination approaches in various solid tumors

 Download the full report (Mandarin)

Download the full report (English)

memo offers free download of a summary slidekit containing recent advances inPD-1/PD-L1 inhibition and PARP inhibition focusing on GI and ovarian cancer presented at the 2020 virtual ESMO meeting supported by BeiGene:

The memo inOncology Special Issue report is produced by Springer, as a supplement ofmemo (the Magazine of European Medical Oncology) and sponsored by Boehringer Ingelheim and BeiGene with an unrestricted educational grant. For more information on the memo inOncology Special Issue series, and for free access to all previous editions, visit the memo-inOncology website.